Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ewelina Nalejska"'
Autor:
Marzena Anna Lewandowska, Ewelina Nalejska, Łukasz Żołna, Aleksandra Chrząstek, Bogdan Żurawski, Magdalena Wiśniewska, Manuela Las-Jankowska, Krzysztof Roszkowski, Janusz Kowalewski
Publikováno v:
Contemporary Oncology, Vol 23, Iss 2, Pp 87-91 (2019)
Externí odkaz:
https://doaj.org/article/1562afdb5dee46b69005effa45cf41f8
Autor:
Łukasz Żołna, Aleksandra Chrząstek, Bogdan Żurawski, Ewelina Nalejska, Magdalena Wiśniewska, Janusz Kowalewski, Marzena Anna Lewandowska, Krzysztof Roszkowski, Manuela Las-Jankowska
Publikováno v:
Contemporary Oncology
Contemporary Oncology, Vol 23, Iss 2, Pp 87-91 (2019)
Contemporary Oncology, Vol 23, Iss 2, Pp 87-91 (2019)
Aim of the study The main purpose of this study was to assess detection of mutations in the epidermal growth factor receptor (EGFR) gene in circulating tumor DNA (ctDNA) as a tool for EGFR tyrosine kinase inhibitor (TKI) monitoring therapy. Material
Autor:
Łukasz Żołna, Katarzyna Kamińska, Janusz Kowalewski, Marta Kubiak, Ewelina Nalejska, Joanna Wojtysiak, Marzena Anna Lewandowska
Publikováno v:
Molecular Diagnosis & Therapy
Epigenetic patterns, such as DNA methylation, histone modifications, and non-coding RNAs, can be both driver factors and characteristic features of certain malignancies. Aberrant DNA methylation can lead to silencing of crucial tumor suppressor genes
Autor:
Dorota Porowińska, Anna Bajek, Tomasz Kloskowski, Małgorzata Maj, Lidia Gackowska, Ewelina Nalejska, Tomasz Drewa
Publikováno v:
Journal of cellular biochemistry. 118(6)
Mesenchymal stem cells (MSCs) are known to interact with cancer cells through direct cell-to-cell contact and secretion of paracrine factors, although their exact influence on tumor progression in vivo remains unclear. To better understand how fetal
Autor:
Katarzyna Kamińska, Bogdan Zurawski, Krzysztof Roszkowski, Janusz Kowalewski, Tomasz Mierzwa, Ewelina Nalejska, Marzena Anna Lewandowska
Publikováno v:
Journal of Clinical Oncology. 36:e13615-e13615
e13615Background: The standard genetic preventive test in Poland covered 3-5 of the most common mutations, including BRCA1: c.5266dupC, c.181T > G, c.4034delA and BRCA2: c.6174delT, c.5972C > T. Re...